Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2022 Earnings Call Transcript
Operator: Good morning and welcome to Voyager Therapeutics 2022 Fourth Quarter and Year End Conference Call. All participants are now in listen-only mode.
Voyager Therapeutics Inc. (VYGR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | EcoR1 Capital Oleg Nodelman | 4,753,907 | $28,998,833 | 0.88% | |
| 2. | Armistice Capital Steven Boyd | 3,396,000 | $20,715,600 | 0.36% | |
| 3. | D E Shaw D. E. Shaw | 688,700 | $4,201,070 | -3% | 0% |
| 4. | Citadel Investment Group Ken Griffin | 161,917 | $987,694 | -28% | 0% |
| 5. | Caxton Associates LP Bruce Kovner | 106,696 | $650,846 | -22% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.88 | 4,395,588 | Large Shareholder | 8,575,316 | 2023-02-23 | Filing | |
| $5.66 | 376,000 | Large Shareholder | 4,753,907 | 2022-06-23 | Filing | |
| $5.28 | 101,400 | Large Shareholder | 4,377,907 | 2022-06-21 | Filing | |
| $11.96 | 4,179,728 | Large Shareholder | 4,179,728 | 2019-03-12 | Filing | |
| $19.39 | 3,000 | Director | 76,588 | 2018-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.76 | 2,193 | Officer | 65,360 | 2023-03-20 | Filing | |
| $7.76 | 3,654 | Officer | 72,876 | 2023-03-20 | Filing | |
| $7.76 | 4,410 | Officer | 102,200 | 2023-03-20 | Filing | |
| $8.20 | 15,373 | Officer | 76,530 | 2023-03-15 | Filing | |
| $7.45 | 3,297 | Officer | 106,610 | 2023-02-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 5,428,933 | $33,116,491 | 25.95% | |
| 2. | 1,955,172 | $11,926,549 | 0% | |
| 3. | 842,924 | $5,141,837 | 0% | |
| 4. | 605,659 | $3,694,520 | 0.01% | |
| 5. | 267,253 | $1,630,243 | 0% |
News See All
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2022 Earnings Call Transcript
Operator: Good morning, and welcome to Voyager Therapeutics Third Quarter 2022 Conference Call. All participants are now in a listen-only mode.
5 Best Biotech Stocks Under $5
NuCana plc (NASDAQ:NCNA) is a UK-based biotech company focused on discovering treatments for different types of cancer.
10 Best Stocks for Beginners with Little Money
In this article we will take a look at the 10 best stocks for beginners with little money.
10 Best Biotech Stocks Under $6 in 2021
In this article we will take a look at the 10 best biotech stocks under $6 in 2021.
Is VYGR A Good Stock To Buy Now?
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of September...
Hedge Funds Are Selling Voyager Therapeutics, Inc. (VYGR)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter.
Is Voyager Therapeutics, Inc. (VYGR) Going To Burn These Hedge Funds ?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Is Voyager Therapeutics, Inc. (VYGR) Going To Burn These Hedge Funds ?
The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small...
Did Hedge Funds Drop The Ball On Voyager Therapeutics, Inc. (VYGR) ?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of March.
Billionaire Hedge Funds
